Published in PLoS Med on August 12, 2008
Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol (2010) 2.91
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care (2009) 2.56
Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol (2011) 1.92
Socioeconomic differences in cardiometabolic factors: social causation or health-related selection? Evidence from the Whitehall II Cohort Study, 1991-2004. Am J Epidemiol (2011) 1.90
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care (2013) 1.77
Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet (2009) 1.61
Methodological challenges in mendelian randomization. Epidemiology (2014) 1.61
Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes (2010) 1.38
Examining overweight and obesity as risk factors for common mental disorders using fat mass and obesity-associated (FTO) genotype-instrumented analysis: The Whitehall II Study, 1985-2004. Am J Epidemiol (2011) 1.29
Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. J Clin Endocrinol Metab (2009) 1.27
Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biol Psychiatry (2015) 1.13
Association of lifecourse socioeconomic status with chronic inflammation and type 2 diabetes risk: the Whitehall II prospective cohort study. PLoS Med (2013) 1.13
Mendelian randomization in nutritional epidemiology. Nutr Rev (2009) 1.10
Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep (2014) 1.07
SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinformatics (2008) 1.06
Cognitive Behavioral Therapy and Tai Chi Reverse Cellular and Genomic Markers of Inflammation in Late-Life Insomnia: A Randomized Controlled Trial. Biol Psychiatry (2015) 0.99
The many weak instruments problem and Mendelian randomization. Stat Med (2014) 0.97
Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health (2010) 0.97
Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol (2015) 0.96
Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol (2016) 0.93
Chronic inflammation role in the obesity-diabetes association: a case-cohort study. Diabetol Metab Syndr (2013) 0.91
Metabolic rescue of obese adipose-derived stem cells by Lin28/Let7 pathway. Diabetes (2013) 0.91
Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity. Oncotarget (2015) 0.86
The causal effect of vitamin D binding protein (DBP) levels on calcemic and cardiometabolic diseases: a Mendelian randomization study. PLoS Med (2014) 0.86
Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study. Osteoporos Int (2013) 0.82
Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study. PLoS One (2011) 0.81
Mendelian Randomization and Type 2 Diabetes. Cardiovasc Drugs Ther (2016) 0.79
What is the impact of n-3 PUFAs on inflammation markers in Type 2 diabetic mellitus populations?: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis (2016) 0.78
Inverse association linking serum levels of potential antioxidant vitamins with C-reactive protein levels using a novel analytical approach. Br J Nutr (2016) 0.78
More evidence against a causal association between C-reactive protein and diabetes. PLoS Med (2008) 0.77
Meta-analysis of haplotype-association studies: comparison of methods and empirical evaluation of the literature. BMC Genet (2011) 0.77
Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. PLoS Med (2016) 0.77
The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia (2012) 0.77
Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort. Diabetologia (2016) 0.76
Three missense variants of metabolic syndrome-related genes are associated with alpha-1 antitrypsin levels. Nat Commun (2015) 0.76
Mendelian randomization studies of biomarkers and type 2 diabetes. Endocr Connect (2015) 0.76
Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort. BMC Endocr Disord (2014) 0.76
C-reactive protein and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus. Int J Ophthalmol (2016) 0.75
Genetic markers of inflammation may not contribute to metabolic traits in Mexican children. PeerJ (2016) 0.75
A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature. PLoS One (2016) 0.75
Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European Prospective Investigation into Cancer--Norfolk study. Cardiovasc Diabetol (2015) 0.75
High-sensitive C-reactive protein and risk of incident type 2 diabetes: a case-control study nested within the Singapore Chinese Health Study. BMC Endocr Disord (2017) 0.75
Associations between actigraphy-assessed sleep, inflammatory markers, and insulin resistance in the Midlife Development in the United States (MIDUS) study. Sleep Med (2016) 0.75
Neutrophil-to-Lymphocyte Ratio for Risk Assessment in Coronary Artery Disease and Carotid Artery Atherosclerosis. J Cardiovasc Ultrasound (2016) 0.75
Systolic Blood Pressure and Risk of Type 2 Diabetes: a Mendelian Randomization Study. Diabetes (2016) 0.75
Acute-phase proteins and incidence of diabetes: a population-based cohort study. Acta Diabetol (2016) 0.75
A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med (2014) 0.75
Effect of metformin on insulin-resistant endothelial cell function. Oncol Lett (2015) 0.75
Causal Genetic Inference Using Haplotypes as Instrumental Variables. Genet Epidemiol (2015) 0.75
CRP-level-associated polymorphism rs1205 within the CRP gene is associated with 2-hour glucose level: The SAPPHIRe study. Sci Rep (2017) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Inflammation and metabolic disorders. Nature (2006) 33.33
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 32.97
Health inequalities among British civil servants: the Whitehall II study. Lancet (1991) 24.79
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Cohort Profile: the Whitehall II study. Int J Epidemiol (2004) 7.63
Obesity, inflammation, and insulin resistance. Gastroenterology (2007) 7.54
C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet (2005) 5.51
Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res (2007) 4.92
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia (1997) 3.34
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation (2006) 3.15
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet (2005) 2.71
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol (2003) 2.63
What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ (2005) 2.50
The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes (2001) 2.47
Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab (2006) 2.43
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis (2001) 2.40
C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med (2003) 2.05
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet (2003) 1.98
Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes (2007) 1.86
C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia (2004) 1.85
Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med (2006) 1.82
Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care (2007) 1.80
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.76
Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes (2007) 1.74
Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord (2003) 1.63
Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes (2000) 1.58
Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res (2005) 1.56
C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol (2003) 1.43
Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis (2002) 1.42
Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis (2005) 1.40
Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes (2005) 1.40
A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis (2005) 1.26
IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes (2006) 1.18
A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab (2003) 1.17
Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes (2003) 1.14
Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol (2007) 1.04
Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men. Diabetes (2006) 1.02
Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes (2004) 0.99
Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) (2005) 0.92
Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur Heart J (2006) 0.91
Variants in the CRP gene as a measure of lifelong differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study, 1980-2001. Am J Epidemiol (2007) 0.89
Prospective relation of C-reactive protein with type 2 diabetes: response to Han et al. Diabetes Care (2003) 0.87
Letter by Timpson et al regarding article, "Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level". Circulation (2006) 0.82
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 32.97
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol (2012) 11.79
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet (2009) 9.90
Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet (2012) 9.43
Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med (2008) 9.39
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Problems of reporting genetic associations with complex outcomes. Lancet (2003) 8.11
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet (2008) 7.31
Indicators of socioeconomic position (part 1). J Epidemiol Community Health (2006) 7.09
Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol (2012) 6.91
A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet (2007) 6.87
Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ (2007) 6.73
Birth weight and risk of type 2 diabetes: a systematic review. JAMA (2008) 6.73
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet (2005) 6.59
Prediabetes: a high-risk state for diabetes development. Lancet (2012) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet (2004) 6.37
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet (2005) 5.51
Childhood obesity. Lancet (2010) 5.47
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30
Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. Hypertension (2007) 5.20
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet (2009) 4.96
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Treatment of periodontitis and endothelial function. N Engl J Med (2007) 4.83
Childhood socioeconomic circumstances and cause-specific mortality in adulthood: systematic review and interpretation. Epidemiol Rev (2004) 4.74
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2011) 4.71
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Exercise for depression. Cochrane Database Syst Rev (2013) 4.30
A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep (2007) 4.25